21 completed, 8 terminated, 4 withdrawn, 1 active not recruiting. 35 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 35 | Completed 21, Terminated 8, Withdrawn 4, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 8 | Completed 5, Terminated 2, Withdrawn 1 |
Follow belinostat: new trials by email Literature Review of belinostat trials Research Report on belinostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-10-30 |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment Belinostat, Biopsy Procedure, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2023-03-01 | 2026-09-18 |
| Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma Belinostat, Durvalumab - Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma | Phase 1 | Completed | University of Utah | 7 | 2022-01-14 | 2026-10-14 |
| Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics Ribociclib, Belinostat - Metastatic Breast Cancer, Recurrent Ovarian Carcinoma | Phase 1 | Terminated | University of Utah | 12 | 2021-05-03 | 2026-09-04 |
| Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer Talazoparib, Belinostat - Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1 | Completed | University of Michigan Rogel Cancer Center | 26 | 2021-03-04 | 2025-01-23 |
| Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation Belinostat, nivolumab, ipilimumab - Metastatic Adenocarcinoma | Phase 1 | Withdrawn | University of Utah | 2020-10-01 | 2020-10-28 | |
| Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials Belinostat, Atazanavir - Solid Tumor, Hematological Malignancies | Phase 1 | Completed | Acrotech Biopharma Inc. | 8 | 2019-08-05 | 2023-05-03 |
| Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Belinostat, Pevonedistat - Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome | Phase 1 | Terminated | National Cancer Institute (NCI) | 18 | 2019-06-20 | 2026-03-03 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Belinostat, Carfilzomib, Copanlisib Hydrochloride - Breast Adenocarcinoma, Metastatic Breast Carcinoma | Phase 1 | Terminated | Mayo Clinic | 17 | 2018-03-27 | 2025-05-26 |
| Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas volasertib, belinostat - Relapsed and Refractory Aggressive B- and T-cell Lymphomas, Lymphoma | Phase 1 | Withdrawn | Yale University | 2016-10-01 | 2017-12-22 | |
| Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma Busulfan, Caphosol, Glutamine - Lymphoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2016-06-01 | 2016-05-04 | |
| Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes Belinostat IV - Solid Tumors, Hematological Malignancies | Phase 1 | Completed | Acrotech Biopharma Inc. | 17 | 2016-04-27 | 2025-10-20 |
| To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment. Belinostat - Relapsed/Refractory Solid Tumors/Hematological Malignancies | Phase 1 | Terminated | Acrotech Biopharma Inc. | 18 | 2016-03-01 | 2019-11-20 |
| A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma Belinostat, Rituximab, Cisplatin - Lymphoma | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2015-12-01 | 2016-01-06 | |
| Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia Adavosertib, Belinostat, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 1 | Terminated | National Cancer Institute (NCI) | 20 | 2015-08-18 | 2026-01-30 |
| Carfilzomib Plus Belinostat in Relapsed/Refractory NHL Carfilzomib, Belinostat - Non-Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | Completed | Massachusetts General Hospital | 19 | 2014-10-01 | 2018-01-25 |
| Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer Belinostat - Advanced Cancer | Phase 1 | Completed | Acrotech Biopharma Inc. | 6 | 2013-09-01 | 2020-01-03 |
| Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) Belinostat, CHOP - Peripheral T-cell Lymphoma | Phase 1 | Completed | Acrotech Biopharma Inc. | 23 | 2013-05-01 | 2020-01-03 |
| Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction Belinostat - Neoplasms, Lymphomas | Phase 1 | Completed | National Cancer Institute (NCI) | 72 | 2011-01-10 | 2019-03-26 |
| MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC Belinostat, Carboplatin, Paclitaxel - Stage IV Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Acrotech Biopharma Inc. | 23 | 2010-12-01 | 2020-01-06 |
Showing 20 of 35. Sign in to see all of them.
Breast Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (5) · Leukemia, Myeloid, Acute (5) · Lymphoma (5) · Lymphoma, Non-Hodgkin (5) · Ovarian Neoplasms (5) · Hematologic Neoplasms (4) · Hodgkin Disease (4) · Lung Neoplasms (4) · Lymphoma, B-Cell, Marginal Zone (4) · Lymphoma, Follicular (4) · Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, T-Cell (4) · Lymphoma, T-Cell, Cutaneous (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4)
National Cancer Institute (NCI) (10) · Acrotech Biopharma Inc. (6) · Valerio Therapeutics (5) · University of Utah (3) · M.D. Anderson Cancer Center (2) · City of Hope Medical Center (1) · Herlev Hospital (1) · Holy Cross Hospital, Florida (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · Spectrum Pharmaceuticals, Inc (1) · University of Michigan Rogel Cancer Center (1) · Virginia Commonwealth University (1) · Yale University (1)
United States (28) · Denmark (4) · United Kingdom (4) · Canada (1) · France (1) · Germany (1) · New Zealand (1) · Singapore (1) · Spain (1)
Wasim Khan, MD (2) · Anish Thomas, M.D. (1) · Beata Holkova, MD (1) · Brian Matthews, MD (1) · Christina Poh (1) · Danielle A Shafer (1) · Erard Gilles, MD (1) · George Wilding (1) · Grzegorz S. Nowakowski, M.D. (1) · Iris Isufi, MD (1) · Jason R. Westin, MD (1) · Jennifer E Amengual (1) · Jeremy Abramson, MD (1) · Jon L Andersen, MD (1)
PMID 23382909, PMID 25962426, PMID 29951694, PMID 33602316, PMID 39821392
P30CA033572 (2), U01CA062491 (2), UM1CA186644 (2), N01CM00100 (1), N01CM62205 (1), P30CA014599 (1), RC2CA148431 (1), U01CA062505 (1), U01CA069852 (1), U01CA099168 (1), U01CA099176 (1), U01CA132123 (1), U54CA209978 (1), UM1CA186689 (1), UM1CA186716 (1)